ROKIT Healthcare, an artificial intelligence (AI)-based regenerative medicine platform corporations, said on the 10th that it has decided to register a patent in Japan for core foundational technology related to kidney regeneration.
The patent approved for registration covers a "composition and medical kit for kidney treatment using omentum, and a regenerative patch utilizing them." It centers on technology that uses AI to analyze a patient's blood, urine, medical imaging, and lifestyle data to predict the risk of kidney function decline in advance, and then uses the patient's own cells and bioink to produce micro kidney tissue and a regenerative patch with a 3D bioprinter.
The manufactured patch is implanted with a small incision to slow or help recover kidney function deterioration. Simply put, it is a regenerative treatment technology that predicts with AI and implants a 3D-printed "custom kidney patch" made from the patient's cells.
ROKIT Healthcare's strategy is to protect the entire process—from AI prediction to long-term monitoring to patient-customized regenerative procedures—as a single "AI kidney regeneration platform," thereby building an intellectual property (IP) barrier in Japan. The company aims to prevent latecomers from copying the technology and, in the long term, to secure platform competitiveness in the Japanese market.
A company representative said, "We plan to pursue joint research and pilot programs with Japanese university hospitals and large hospitals, using this decision to register the Japanese patent as a springboard," and added, "While making Japan a Northeast Asia AI kidney regeneration hub, we will expand the platform to Korea, the United States, and Europe based on our foothold in Japan."